[1] Lawrence RC,Felson DT,Helmick CG,et al.Estimates of the prevalence of arthritis and other rheumatic conditions in the United States:part Ⅱ[J].Arthritis Rheum,2008,58(1):26-35.[2] Robinson PC,Taylor WJ,Merriman TR.Systematic review of the prevalence of gout and hyperuricaemia in Australia[J].Intern Med J,2012,42(9):997-1007.[3] Grassi D,Ferri L,Desideri G,et al.Chronic hyperuricemia,uric acid deposit and cardiovascular risk[J].Curr Pharm Design,2013,19(13):2432.[4] 许海燕,顼志敏,陆宗良.中国成人血脂异常防治指南 (2007) 概要与解读 [J].中华老年心脑血管病杂志,2008,10(3):238-240.[5] Lu W,Song K,Wang Y,et al.Relationship between serum uric acid and metabolic syndrome:an analysis by structural equation modeling[J].J Clin Lipidol,2012,6(2):159-167.[6] MarottaT,LiccardoM,SchettiniF,et al.Association of hyperuricemia with conventional cardiovascular risk factors in elderly patients[J].J Clin Hypertens (Greenwich),2015(1):27-32.[7] Xu J,Peng H,Ma Q,et al.Associations of non-high density lipoprotein cholesterol and traditional blood lipid profiles with hyperuricemia among middle-aged and elderly Chinese people:a community-based cross-sectional study[J].Lipids Health Dis,2014,13(1):117.[8] Tinahones JF,Perez-Lindon G,C-Soriguer FJ,et al.Dietary alterations in plasma very low density lipoprotein levels modify renal excretion of urates in hyperuricemic-hypertriglyceridemic patients 1[J].J Clin Endocrinol Metab,1997,82(4):1188-1191.[9] Choi HK,Ford ES,Li C,et al.Prevalence of the metabolic syndrome in patients with gout:the third national health and nutrition examination survey[J].Arthrit Care Res,2007,57(1):109-115.[10] Becker MA,Schumacher HR,Espinoza LR,et al.The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout:the confirms trial[J].Arthrit Care Res,2010,12:R63.[11] Real JT,Martínez-Hervás S,García-García AB,et al.Circulating mononuclear cells nuclear factor-kappa B activity,plasma xanthine oxidase,and low grade inflammatory markers in adult patients with familial hypercholesterolaemia[J].Eur J Pharmacol,2010,40(2):89-94.[12] Povoa Jr H,Sa LD,Lessa VM.Xanthine oxidase and triglycerides in serum of patients with hyperlipoproteinemia,type Ⅳ[J].Biomed Biochim Acta,1983,43(10):1201-1203.[13] Sezai A,Soma M,Nakata K,et al.Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial)[J].Circ J,2013,77(8):2043-2049.[14] Sánchez-Lozada LG,Tapia E,Bautista-García P,et al.Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome[J].Am J PhysiolRenal,2008,294(4):F710-F718.[15] Reungjui S,Roncal CA,Mu W,et al.Thiazide diuretics exacerbate fructose-induced metabolic syndrome[J].J Am Soc Nephrol,2007,18(10):2724-2731.[16] Ziga N,Becic F.Allopurinol effect on values of lipid profile fractions in hyperuricemic patients diagnosed with metabolic syndrome[J].Mater Sociomed,2013,25(3):167.[17] Okamoto K,Eger BT,Nishino T,et al.An extremely potent inhibitor of xanthine oxidoreductase crystal structure of the enzyme-inhibitor complex and mechanism of inhibition[J].J Biol Chem,2003,278(3):1848-1855.[18] 时佳,沈震,苗慧,等.血脂水平与慢性丙型肝炎患者抗病毒疗效的相关性分析[J].临床肝胆病杂志,2014,30(6):496-500. |